Welcome to our dedicated page for ProKidney SEC filings (Ticker: PROK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Each ProKidney Corp filing blends biotech science with complex accounting鈥攈undreds of pages that hide critical answers on REACT Phase 3 timelines, RMAT interactions, and the company鈥檚 cash runway. Finding the exact table that shows quarterly burn-rate or the footnote explaining trial protocol amendments can cost analysts hours.
Stock Titan solves that problem in real time. Our AI-powered summaries translate ProKidney SEC filings into clear language, flagging what matters in every document type: the 10-K annual report that details manufacturing scale-up plans, the 10-Q quarterly earnings report with updated R&D spending, and the Form 4 insider transactions that may precede clinical read-outs. Need to monitor a sudden 8-K material event? You鈥檒l get an alert鈥攁nd an explanation鈥攎inutes after EDGAR posts it.
Browse every submission without the noise:
- 鈥淧roKidney insider trading Form 4 transactions鈥� feed shows executive stock moves as they happen.
- 鈥淧roKidney quarterly earnings report 10-Q filing鈥� highlights shifts in cash reserves and trial costs.
- 鈥淧roKidney annual report 10-K simplified鈥� breaks down risk factors around CKD market size and regulatory pathways.
- 鈥淧roKidney proxy statement executive compensation鈥� connects leadership incentives to trial milestones.
- 鈥淧roKidney 8-K material events explained鈥� decodes sudden disclosures on FDA meetings or manufacturing updates.
Whether you鈥檙e confirming cash runway before dilution risk, tracking 鈥淧roKidney Form 4 insider transactions real-time鈥�, or simply understanding ProKidney SEC documents with AI, our platform keeps you ahead of the next data point. All filings, all formats鈥攄elivered with expert context you can act on.
ProKidney Corp. (Nasdaq: PROK) furnished a Current Report on Form 8-K stating that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1, and the filing also references an Inline XBRL cover page file for the report.
The report notes that the furnished press release and related information are not being "filed" for purposes of certain Exchange Act liabilities and will not be incorporated by reference into other registration statements unless expressly stated. The filing identifies ProKidney as an emerging growth company and is signed on behalf of the registrant by Chief Financial Officer James Coulston.
ProKidney Corp. reported a substantial operating loss as it advances its lead autologous cell therapy, rilparencel, through late-stage trials while funding clinical and manufacturing operations. For the six months ended June 30, 2025 the consolidated net loss before noncontrolling interest was $74.9 million, cash and cash equivalents were $84.9 million and marketable securities totaled $209.8 million, giving combined short-term liquidity of about $294.7 million. Total assets were $372.1 million and stockholders' deficit was $1.0025 billion, reflecting a large redeemable noncontrolling interest of $1.342 billion.
The company is progressing Phase 3 PROACT 1 to support accelerated approval of rilparencel: the FDA agreed that eGFR slope can serve as a surrogate endpoint for an accelerated BLA and specified an acceptable effect size of at least 1.5 mL/min/1.73m2/year. ProKidney completed the REGEN-007 Phase 2 trial showing in one dosing arm a statistically significant improvement in annual eGFR slope of 4.6 mL/min/1.73m2/year (p<0.001). The company has enrolled nearly half the patients required for the accelerated approval analysis, with topline eGFR slope readout anticipated in Q2 2027.
Form 8-K filing highlights ProKidney Corp. (Nasdaq: PROK) furnished an 8-K dated 15 July 2025 to disclose two items under Regulation FD and Other Events.
Investor presentation (Item 7.01) Management placed an updated slide deck covering business, clinical studies, development plans and financial position on the company鈥檚 investor website and attached it as Exhibit 99.2. The company emphasizes that the material should be viewed in the context of prior SEC filings and does not undertake to update it unless required by law.
Press release on FDA alignment (Items 7.01 & 8.01) Exhibit 99.1 contains a same-day press release announcing 鈥渃onfirmation of alignment with the U.S. Food and Drug Administration on the accelerated approval pathway for rilparencel,鈥� the company鈥檚 lead asset. The first two paragraphs of that release are incorporated by reference into Item 8.01, signifying potential material relevance.
No financial data The filing does not include earnings figures, balance-sheet information or guidance. It is being furnished rather than filed, so it is not subject to Section 18 liability.
Key takeaway for investors The disclosed FDA alignment represents a regulatory milestone that may reduce development risk for rilparencel. However, without accompanying clinical data, timelines or financial metrics, the magnitude of impact cannot be fully assessed from this filing alone.
FAQ
What is the current stock price of ProKidney (PROK)?
What is the market cap of ProKidney (PROK)?
